Evidence map›Paper›PMID 29699534›Full record

SynthesisBMC public health2018

High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies.

Moussa Lingani, Tomoyuki Akita, Serge Ouoba, Armel Moumini Sanou, Aya Sugiyama, Zekiba Tarnagda, Masayuki Ohisa, Halidou Tinto, Shunji Mishiro, Junko Tanaka

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 10 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 10 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Review
  13. Immune response to GeneVac-BIJID regions · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Evaluation of the Diagnostic Performances of the SD-BiolineDiagnostics (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Moussa LinganiUnité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, BP 218, Burkina Faso.
Tomoyuki AkitaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Serge OuobaUnité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, BP 218, Burkina Faso.
Armel Moumini SanouUnité des Maladies à potentiel épidémiques, Maladies émergentes et Zoonoses, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
Aya SugiyamaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Zekiba TarnagdaUnité des Maladies à potentiel épidémiques, Maladies émergentes et Zoonoses, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
Masayuki OhisaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Halidou TintoUnité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, BP 218, Burkina Faso.
Shunji MishiroDepartment of Medical Sciences, Toshiba General Hospital, Tokyo, Japan.
Junko TanakaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. jun-tanaka@hiroshima-u.ac.jp.ORCID 0000-0002-5669-4051
Hiroshima University · JPInstitut de Recherche en Sciences de la Santé · BFTokyo Shinagawa Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) infection was long considered an important public health concern in Burkina Faso and still represents a major cause of liver cancer and cirrhosis in the active population. To counter the problem, a national strategic plan was developed and adopted in July 2017 to coordinate viral hepatitis elimination's efforts. However evidence to support its implementation remains scanty and scattered. The main purpose of this study was to summarize available information from per-reviewed articles published over the last two decades to accurately estimate the prevalence of HBV infection in Burkina Faso.

methodsWe conducted a systematic search with meta-analysis of scientific articles using Science-Direct, Web-of-Science, PubMed/Medline, and Google Scholar. We systematically assessed all relevant publications that measured the prevalence of hepatitis B surface antigen and which were published between 1996 and 2017. We estimated the national HBV prevalence and its 95% confident interval. We subsequently adjusted the meta-analysis to possible sources of heterogeneity.

resultsWe retrieved and analyzed a total of 22 full text papers including 99,672 participants. The overall prevalence was 11.21%. The prevalence after adjustment were 9.41%, 11.11%, 11.73% and 12.61% in the general population, pregnant women, blood donors and HIV-positive persons respectively. The prevalence was higher before implementation of HBV universal vaccination and decreased from 12.80% between 1996 and 2001 to 11.11% between 2012 and 2017. The prevalence was also higher in rural area 17.35% than urban area 11.11%. The western regions were more affected with 12.69% than the central regions 10.57%. The prevalence was 14.66% in the boucle of Mouhoun region and 14.59 in the center-west region. Aggregate data were not available for the other regions.

conclusionsHBV has clearly an important burden in Burkina Faso as described by its high prevalence and this problem significantly challenges the national health care system. There is an urgent need for effective public health interventions to eliminate the problem. However, higher quality data are needed to produce reliable epidemiological estimates that will guide control efforts towards the achievement of the national strategic plan's goals.

Indexed as

Burkina FasoEpidemiologic StudiesHepatitis BHumansPrevalenceBurkina FasoEpidemiologyHepatitis BMeta-analysisViral infection

Identifiers

PMID29699534
PMCPMC5921387
OpenAlexW2806481305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.